|
A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment Clinical research trials and A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment. A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment clinical trial. Human subjects often obtain the finest healthcare possible for their A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment
A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment
For Condition: HIV Infections
Status: Completed
Sponsor(s): Sarawak MediChem Pharmaceuticals ,
Synopsis: The purpose of this study is to test the safety and effectiveness of a new non-nucleoside reverse transcriptase inhibitor (NNRTI), (+)-calanolide A, in HIV-positive patients who have never received anti-HIV treatment.
Details: Patients are randomized into 2 cohorts, with Cohort 2 receiving a higher dosage than Cohort 1. Patients in each cohort receive either (+)-calanolide A or a placebo for 14 days, followed by a 14-day follow-up period. Following study treatment, patients may elect to receive an open-label, 6-month course of anti-HIV drugs to be selected by and administered under the care of the patient's physician.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Pharmacokinetics Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria You may be eligible for this study if you: - Are HIV-positive. - Have a CD4 count of at least 250 cells/mm3. - Have an HIV count (viral load) of at least 5,000 copies/ml. - Are at least 18 years old. Exclusion Criteria You will not be eligible for this study if you: - Have received prescription or nonprescription medications within 14 days of study entry, or if you will need to take any of these medications during the study. - Have ever received anti-HIV medications. - Test positive for hepatitis B. - Have received a blood (or red blood cell) transfusion within 3 months prior to study entry. - Have severe diarrhea. - Have severe heart, liver, kidney, or neurological (brain and spinal cord) disease. - Have hemophilia or another blood disorder. - Have received certain medications or vaccines within 30 days prior to study entry. - Have received chemotherapy or radiation within 16 days prior to study entry, or if you will need either of these during the study.
Total Enrollment: 32
Location and Contact Information:
Univ of Maryland Institute of Human Virology
Baltimore, Maryland, 212011192
United States
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida, 32960
United States
Cook County Hosp
Chicago, Illinois, 60612
United States
Beth Israel Med Ctr
New York City, New York, 10003
United States
Anderson Clinical Research / Inc
Pittsburgh, Pennsylvania, 15213
United States
Univ of Texas / Med Branch at Galveston
Galveston, Texas, 775550835
United States
Boston Med Ctr / Clinical Research Office
Boston, Massachusetts, 02118
United States
South Florida Bioavailability Clinic
Miami, Florida, 331813405
United States
Vanderbilt Univ Med Ctr
Nashville, Tennessee, 37212
United States
Additional Information:
Study ID Numbers: 297A; 57CL-9802
Study Start Date:
Record last reviewed: July 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002243
Other Hiv Infections Studies:
1. A Study of Zidovudine in HIV-Infected Patients with Kidney Problems
2. Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV Drugs
3. A Comparison of Two Types of Injected Nutritional Supplements in Patients with AIDS and Pneumocystis carinii Pneumonia (PCP)
4. Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection
5. A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients with Advanced HIV Infection
Related Studies:
Other HIV Infections Clinical Trials
Other Florida Clinical Trials
Other Miami Clinical Trials
A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment
|
|
|
|
|
|
|
|